Summus Laser System Horizon

Summus Laser System Horizon

Class IV Cold laser is a quantum leap in laser technology and has been designed and engineered using decades of sophisticated research and technology.

Proven to biostimulate tissue repair and growth, Class IV laser therapy is a non-surgical, drug-free treatment option designed to treat acute to chronic pain.

The Horizon laser system includes a video camera that provides a Video Chat with Summus professionals and allows users to record their Live Training Sessions. The system is designed to provide consistent, precise, reproducible results for your patients.

The complete laser system includes:

Progressive Treatments
A patient can be set-up for a treatment plan. The protocol will vary as the patient progresses through the plan.
Independent Wavelength Control
Each wavelength has a different effect on the body. This allows a condition to receive the optimal therapy.
Automatic Optic Identification
The laser automatically recognizes which optic is being used. This is important from a safety and user experience standpoint, according to the manufacturer.
4 Wavelengths
980nm Improves Circulation; 915nm Enhances Oxygen Delivery; 810nm Increases ATP Production; and 650nm Accelerates Surface Healing.
Phased Protocols
Each protocol is built with multiple phases of wavelengths and pulsing.
Visual Guidance
Motion graphics displayed on screen will guide clinicians through treatments with confidence.
Trigger Point Therapy
Users are guided to corresponding trigger points associated with multiple pain syndromes.
Summus’ exclusive On Call Technology connects with the company’s dedicated staff of knowledgeable laser therapy experts to answer clinical questions, schedule a training, access marketing and service support, and more.

Summus Medical LasersTM deliver specific red and near-infrared wavelengths of laser light to induce a photochemical reaction and therapeutic effect. Laser therapy has been used in Europe since the 1970s and Summus Medical Laser was cleared by the United States Food and Drug Administration (FDA) in 2005.